for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Editas Medicine Inc

EDIT.OQ

Latest Trade

20.39USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.90

 - 

32.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.39
Open
--
Volume
--
3M AVG Volume
12.19
Today's High
--
Today's Low
--
52 Week High
32.44
52 Week Low
17.90
Shares Out (MIL)
49.52
Market Cap (MIL)
1,014.57
Forward P/E
-7.43
Dividend (Yield %)
--

Next Event

Q3 2019 Editas Medicine Inc Earnings Release

Latest Developments

More

Nikko Asset Management Americas Inc Reports 10.01% Passive Stake In Editas Medicine Inc As Of Sept 30

Editas Medicine Reports Q2 Loss Per Share $0.69

Editas Medicine Appoints Cynthia Collins As President And Chief Executive Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Editas Medicine Inc

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Industry

Biotechnology & Drugs

Contact Info

11 Hurley St

+1.617.4019000

http://www.editasmedicine.com/

Executive Leadership

James C. Mullen

Independent Chairman of the Board

Cynthia L. Collins

President, Chief Executive Officer, Director

Eric Ek

Interim Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer

Charles Albright

Chief Scientific Officer

Judith R. Abrams

Chief Medical Officer

Key Stats

2.30 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.020

2017

-2.980

2018

-2.330

2019(E)

-2.758
Price To Earnings (TTM)
--
Price To Sales (TTM)
40.52
Price To Book (MRQ)
5.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.68
Return on Equity (TTM)
-27.59

Latest News

Latest News

BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67

* EDITAS MEDICINE ANNOUNCES FIRST QUARTER 2018 RESULTS AND UPDATE

BRIEF-Editas Medicine Names James Mullen As Chairman Of Board

* EDITAS MEDICINE NAMES JAMES C. MULLEN AS CHAIRMAN OF THE BOARD OF DIRECTORS

BRIEF-Editas Medicine Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing

* EDITAS MEDICINE INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text (http://bit.ly/2GlXQp9) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Editas Medicine Q4 Loss Per Share $0.84

* EDITAS MEDICINE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND UPDATE

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

BRIEF-Editas Medicine Files For Potential Stock Shelf, Size Undisclosed - SEC Filing

* EDITAS MEDICINE INC FILES FOR POTENTIAL STOCK SHELF, SIZE UNDISCLOSED - SEC FILING Source text: (http://bit.ly/2zhhSfB) Further company coverage:

BRIEF-Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock

* EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK

BRIEF-Editas Medicine Announces Offering Of Common Stock

* EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Editas Medicine announces Q3 loss per share $0.64

* Editas Medicine announces third quarter 2017 results and update

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

* Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10

BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10

* Editas Medicine Inc - announced that company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10)

BRIEF-Editas Medicine Q2 loss per share $0.65

* Editas Medicine announces second quarter 2017 results and update

BRIEF-Editas Medicine achieves milestone under Juno Therapeutics collaboration

* Editas Medicine achieves milestone under Juno Therapeutics collaboration for technical progress towards overcoming the tumor microenvironment Source text for Eikon: Further company coverage:

BRIEF-Editas Medicine names Andrew Hirsch to board of directors

* Hirsch will also serve as chairman of audit committee of board, hirsch is currently chief financial officer of agios pharmaceuticals Source text for Eikon: Further company coverage:

BRIEF-Editas Medicine Q1 loss per share $0.85

* Editas Medicine announces first quarter 2017 results and update

BRIEF-Editas announces pricing of $90 million offering of common stock

* Editas medicine, inc. Announces pricing of $90 million offering of common stock

BRIEF-Editas medicine announces proposed offering of common stock

* Editas Medicine, Inc., announces proposed offering of common stock

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye treatments under a research and development deal between the two companies.

BRIEF-Allergan and Editas Medicine enter into strategic research and development alliance

* Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up